Syndax Showcases Promising Revuforj® Data for Acute Leukemia at ASH Annual Meeting Syndax Pharmaceuticals revealed significant data on Revuforj® (revumenib) for treating acute leukemias at the 66th ASH Annual Meeting, demonstrating high efficacy and tolerability in patients.

Syndax Showcases Promising Revuforj® Data for Acute Leukemia at ASH Annual Meeting #United_States #San_Diego #Revuforj #Syndax #acute_leukemia